瑞康医药
(002589)
| 流通市值：45.34亿 | | | 总市值：49.96亿 |
| 流通股本：13.66亿 | | | 总股本：15.05亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 5,746,973,100.09 | 5,049,888,378.73 | 3,744,625,609.4 | 4,241,083,430.77 |
| 结算备付金 | - | - | 0 | - |
| 拆出资金 | - | - | 0 | - |
| 交易性金融资产 | 5,000,000 | 0 | 0 | - |
| 衍生金融资产 | - | 0 | 0 | - |
| 应收票据及应收账款 | 3,777,982,815.35 | 3,944,152,972.65 | 4,003,569,630.9 | 4,173,053,386.47 |
| 其中：应收票据 | 172,199,295.14 | 130,873,720.08 | 292,697,260.72 | 439,795,378.74 |
| 应收账款 | 3,605,783,520.21 | 3,813,279,252.57 | 3,710,872,370.18 | 3,733,258,007.73 |
| 应收款项融资 | 65,481,529.45 | 97,224,613.57 | 172,111,169.43 | 210,243,637.76 |
| 预付款项 | 75,925,496.37 | 114,116,568.45 | 55,863,094.15 | 133,010,463.73 |
| 应收保费 | - | - | 0 | - |
| 应收分保账款 | - | - | 0 | - |
| 应收分保合同准备金 | - | - | 0 | - |
| 其他应收款合计 | 674,323,504.98 | 703,296,383.26 | 717,083,434.48 | 944,694,951.74 |
| 其中:应收利息 | - | - | 547,584.82 | - |
| 应收股利 | - | - | 0 | - |
| 买入返售金融资产 | - | - | 0 | - |
| 存货 | 631,425,913.53 | 651,644,982.76 | 715,297,272.79 | 692,925,487.73 |
| 合同资产 | - | 0 | - | - |
| 一年内到期的非流动资产 | - | 0 | - | - |
| 其他流动资产 | 45,409,252.06 | 44,586,323.49 | 44,556,961.27 | 48,017,977.94 |
| 流动资产合计 | 11,022,521,611.83 | 10,604,910,222.91 | 9,453,107,172.42 | 10,443,029,336.14 |
| 非流动资产: | | | | |
| 长期股权投资 | 700,708,533.07 | 700,708,533.07 | 600,708,533.07 | 528,487,606.53 |
| 其他权益工具投资 | 5,217,561 | 5,217,561 | 5,217,561 | 5,217,561 |
| 其他非流动金融资产 | 215,400,000 | 215,400,000 | 215,400,000 | 209,606,198.25 |
| 投资性房地产 | 660,473,149.2 | 666,007,171.71 | 672,043,716.99 | 677,746,256.07 |
| 固定资产 | 1,976,312,997.99 | 1,705,170,786.67 | 1,709,224,050.2 | 1,723,765,788.18 |
| 在建工程 | 18,816,527.58 | 307,387,939.67 | 306,180,018.88 | 310,496,923.38 |
| 生产性生物资产 | - | 0 | 0 | - |
| 油气资产 | - | 0 | 0 | - |
| 使用权资产 | 2,118,804.11 | 2,303,550.25 | 2,431,791.24 | 3,026,093.73 |
| 无形资产 | 488,254,285.35 | 482,794,797.61 | 506,701,052.93 | 519,546,809.84 |
| 开发支出 | 22,096,622.65 | 22,096,622.65 | 22,096,622.65 | 22,096,622.65 |
| 商誉 | 146,667,621.5 | 146,667,621.5 | 146,667,621.5 | 146,667,621.5 |
| 长期待摊费用 | 22,893,996.79 | 25,990,142.8 | 27,589,567.86 | 29,785,913.83 |
| 递延所得税资产 | 312,027,290.29 | 317,379,480.78 | 321,592,755.65 | 303,524,196.07 |
| 其他非流动资产 | 355,659,554.49 | 344,497,043.9 | 380,883,889.86 | 405,957,089.61 |
| 非流动资产合计 | 4,926,646,944.02 | 4,941,621,251.61 | 4,916,737,181.83 | 4,885,924,680.64 |
| 资产总计 | 15,949,168,555.85 | 15,546,531,474.52 | 14,369,844,354.25 | 15,328,954,016.78 |
| 流动负债: | | | | |
| 短期借款 | 4,788,972,253.6 | 4,612,175,886.42 | 4,200,594,440.85 | 5,302,030,849.49 |
| 向中央银行借款 | - | - | 0 | - |
| 吸收存款及同业存放 | - | - | 0 | - |
| 拆入资金 | - | - | 0 | - |
| 交易性金融负债 | - | 0 | 0 | - |
| 衍生金融负债 | - | 0 | 0 | 151,259,900 |
| 应付票据及应付账款 | 4,850,214,506.78 | 4,580,460,780.55 | 3,760,140,703.99 | 3,462,158,024.24 |
| 其中：应付票据 | 3,054,467,287.87 | 2,807,399,547.74 | 1,785,229,133.83 | 1,110,419,812.03 |
| 应付账款 | 1,795,747,218.91 | 1,773,061,232.81 | 1,974,911,570.16 | 2,351,738,212.21 |
| 预收款项 | - | 0 | 0 | 2,775,229.35 |
| 合同负债 | 23,163,251.97 | 14,994,406.14 | 9,444,987.84 | 12,423,111.64 |
| 卖出回购金融资产款 | - | - | 0 | - |
| 应付手续费及佣金 | - | - | 0 | - |
| 应付职工薪酬 | 15,075,926.23 | 14,857,153.94 | 17,710,701.73 | 18,066,070.16 |
| 应交税费 | 11,912,251.08 | 13,618,536.2 | 21,745,876.78 | 29,423,372.07 |
| 其他应付款合计 | 317,069,711.89 | 343,708,307.89 | 386,775,678.14 | 318,627,665.37 |
| 其中:应付利息 | - | - | 0 | - |
| 应付股利 | 3,943,415.4 | 18,586,730.2 | 62,087,799.7 | 91,087,799.7 |
| 应付分保账款 | - | - | 0 | - |
| 代理买卖证券款 | - | - | 0 | - |
| 代理承销证券款 | - | - | 0 | - |
| 一年内到期的非流动负债 | 172,345,270.99 | 27,533,333.34 | 168,687,097.94 | 27,533,333.34 |
| 其他流动负债 | 55,652,165.3 | 48,759,836.13 | 96,826,081.33 | 73,741,653.56 |
| 流动负债合计 | 10,234,405,337.84 | 9,656,108,240.61 | 8,661,925,568.6 | 9,398,039,209.22 |
| 非流动负债: | | | | |
| 长期借款 | 215,279,160.99 | 397,861,263.35 | 234,713,915.46 | 425,398,360.41 |
| 应付债券 | - | 0 | 0 | - |
| 优先股 | - | 0 | 0 | - |
| 永续债 | - | - | 0 | - |
| 租赁负债 | 1,472,133.55 | 1,515,518.58 | 931,095.29 | 2,611,086.82 |
| 长期应付款 | - | 0 | 0 | - |
| 长期应付职工薪酬 | - | 0 | 0 | - |
| 预计负债 | - | 0 | 0 | - |
| 递延收益 | 4,391,881.35 | 4,527,549.38 | 4,567,473.56 | 4,708,662.87 |
| 递延所得税负债 | 42,763,929.84 | 41,894,176.64 | 44,964,636.07 | 44,016,636.08 |
| 其他非流动负债 | - | 0 | 0 | - |
| 非流动负债合计 | 263,907,105.73 | 445,798,507.95 | 285,177,120.38 | 476,734,746.18 |
| 负债合计 | 10,498,312,443.57 | 10,101,906,748.56 | 8,947,102,688.98 | 9,874,773,955.4 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,504,710,471 | 1,504,710,471 | 1,504,710,471 | 1,504,710,471 |
| 其他权益工具 | - | 0 | 0 | - |
| 优先股 | - | 0 | 0 | - |
| 永续债 | - | - | 0 | - |
| 资本公积 | 3,476,810,908.43 | 3,483,074,407.02 | 3,476,810,908.43 | 3,483,074,407.02 |
| 减:库存股 | 101,475,367.91 | 101,475,367.91 | 101,475,367.91 | 60,390,711.95 |
| 其他综合收益 | - | 0 | 0 | - |
| 专项储备 | - | 0 | 0 | - |
| 盈余公积 | 187,298,356.34 | 187,298,356.34 | 187,298,356.34 | 167,362,440.57 |
| 一般风险准备 | - | - | 0 | - |
| 未分配利润 | 241,258,370.52 | 242,661,449.58 | 232,289,235.9 | 254,217,064.29 |
| 归属于母公司股东权益合计 | 5,308,602,738.38 | 5,316,269,316.03 | 5,299,633,603.76 | 5,348,973,670.93 |
| 少数股东权益 | 142,253,373.9 | 128,355,409.93 | 123,108,061.51 | 105,206,390.45 |
| 股东权益合计 | 5,450,856,112.28 | 5,444,624,725.96 | 5,422,741,665.27 | 5,454,180,061.38 |
| 负债和股东权益合计 | 15,949,168,555.85 | 15,546,531,474.52 | 14,369,844,354.25 | 15,328,954,016.78 |
| 公告日期 | 2026-08-21 | 2026-04-25 | 2026-04-23 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |